Financhill
Sell
21

HBIO Quote, Financials, Valuation and Earnings

Last price:
$0.65
Seasonality move :
-0.31%
Day range:
$0.60 - $0.66
52-week range:
$0.60 - $4.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.30x
P/B ratio:
0.45x
Volume:
1.4M
Avg. volume:
362.9K
1-year change:
-84.9%
Market cap:
$28.3M
Revenue:
$94.1M
EPS (TTM):
-$0.29

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HBIO
Harvard Bioscience
$24.2M $0.05 -14.53% -90.91% $4.25
AKYA
Akoya Biosciences
$21.3M -$0.16 8.83% -56.77% $3.48
AZTA
Azenta
$146M $0.06 -11.53% 86.12% $58.67
BNGO
Bionano Genomics
$6.2M -$8.40 -6.63% -95.03% --
BRKR
Bruker
$965.6M $0.74 5.84% 28.06% $68.42
KMTS
Kestra Medical Technologies
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HBIO
Harvard Bioscience
$0.65 $4.25 $28.3M -- $0.00 0% 0.30x
AKYA
Akoya Biosciences
$1.51 $3.48 $74.8M -- $0.00 0% 0.86x
AZTA
Azenta
$36.80 $58.67 $1.7B -- $0.00 0% 2.86x
BNGO
Bionano Genomics
$3.47 -- $9.5M -- $0.00 0% 0.08x
BRKR
Bruker
$45.96 $68.42 $7B 60.47x $0.05 0.44% 2.04x
KMTS
Kestra Medical Technologies
$21.50 -- $1B -- $0.00 0% 21.49x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HBIO
Harvard Bioscience
36.85% 0.845 40.16% 0.35x
AKYA
Akoya Biosciences
84.77% -0.175 56.35% 1.74x
AZTA
Azenta
-- 1.504 -- 3.05x
BNGO
Bionano Genomics
23.43% -0.164 37.24% 0.86x
BRKR
Bruker
54.04% 1.433 23.46% 0.69x
KMTS
Kestra Medical Technologies
-- 0.000 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HBIO
Harvard Bioscience
$14M $11K -11.92% -18.36% 5.88% $1.3M
AKYA
Akoya Biosciences
$11.7M -$7.4M -52.65% -157.22% -41.8% -$9.7M
AZTA
Azenta
$68.7M -$10.9M -7.97% -7.97% -7.4% $22M
BNGO
Bionano Genomics
-$8.4M -$22.6M -121.16% -158.95% -727.05% -$13.3M
BRKR
Bruker
$493.3M $157M 3.22% 6.78% 7.32% $153.3M
KMTS
Kestra Medical Technologies
-- -- -- -- -- --

Harvard Bioscience vs. Competitors

  • Which has Higher Returns HBIO or AKYA?

    Akoya Biosciences has a net margin of 0.07% compared to Harvard Bioscience's net margin of -55.99%. Harvard Bioscience's return on equity of -18.36% beat Akoya Biosciences's return on equity of -157.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    HBIO
    Harvard Bioscience
    57.06% -- $100.3M
    AKYA
    Akoya Biosciences
    62.32% -$0.21 $89.5M
  • What do Analysts Say About HBIO or AKYA?

    Harvard Bioscience has a consensus price target of $4.25, signalling upside risk potential of 555.97%. On the other hand Akoya Biosciences has an analysts' consensus of $3.48 which suggests that it could grow by 130.46%. Given that Harvard Bioscience has higher upside potential than Akoya Biosciences, analysts believe Harvard Bioscience is more attractive than Akoya Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    HBIO
    Harvard Bioscience
    2 0 0
    AKYA
    Akoya Biosciences
    1 7 0
  • Is HBIO or AKYA More Risky?

    Harvard Bioscience has a beta of 1.464, which suggesting that the stock is 46.371% more volatile than S&P 500. In comparison Akoya Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HBIO or AKYA?

    Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akoya Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Akoya Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HBIO or AKYA?

    Harvard Bioscience quarterly revenues are $24.6M, which are larger than Akoya Biosciences quarterly revenues of $18.8M. Harvard Bioscience's net income of $18K is higher than Akoya Biosciences's net income of -$10.5M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Akoya Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.30x versus 0.86x for Akoya Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HBIO
    Harvard Bioscience
    0.30x -- $24.6M $18K
    AKYA
    Akoya Biosciences
    0.86x -- $18.8M -$10.5M
  • Which has Higher Returns HBIO or AZTA?

    Azenta has a net margin of 0.07% compared to Harvard Bioscience's net margin of -9.04%. Harvard Bioscience's return on equity of -18.36% beat Azenta's return on equity of -7.97%.

    Company Gross Margin Earnings Per Share Invested Capital
    HBIO
    Harvard Bioscience
    57.06% -- $100.3M
    AZTA
    Azenta
    46.55% -$0.29 $1.7B
  • What do Analysts Say About HBIO or AZTA?

    Harvard Bioscience has a consensus price target of $4.25, signalling upside risk potential of 555.97%. On the other hand Azenta has an analysts' consensus of $58.67 which suggests that it could grow by 58.7%. Given that Harvard Bioscience has higher upside potential than Azenta, analysts believe Harvard Bioscience is more attractive than Azenta.

    Company Buy Ratings Hold Ratings Sell Ratings
    HBIO
    Harvard Bioscience
    2 0 0
    AZTA
    Azenta
    2 5 0
  • Is HBIO or AZTA More Risky?

    Harvard Bioscience has a beta of 1.464, which suggesting that the stock is 46.371% more volatile than S&P 500. In comparison Azenta has a beta of 1.521, suggesting its more volatile than the S&P 500 by 52.14%.

  • Which is a Better Dividend Stock HBIO or AZTA?

    Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HBIO or AZTA?

    Harvard Bioscience quarterly revenues are $24.6M, which are smaller than Azenta quarterly revenues of $147.5M. Harvard Bioscience's net income of $18K is higher than Azenta's net income of -$13.3M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.30x versus 2.86x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HBIO
    Harvard Bioscience
    0.30x -- $24.6M $18K
    AZTA
    Azenta
    2.86x -- $147.5M -$13.3M
  • Which has Higher Returns HBIO or BNGO?

    Bionano Genomics has a net margin of 0.07% compared to Harvard Bioscience's net margin of -728.57%. Harvard Bioscience's return on equity of -18.36% beat Bionano Genomics's return on equity of -158.95%.

    Company Gross Margin Earnings Per Share Invested Capital
    HBIO
    Harvard Bioscience
    57.06% -- $100.3M
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
  • What do Analysts Say About HBIO or BNGO?

    Harvard Bioscience has a consensus price target of $4.25, signalling upside risk potential of 555.97%. On the other hand Bionano Genomics has an analysts' consensus of -- which suggests that it could grow by 1629.1%. Given that Bionano Genomics has higher upside potential than Harvard Bioscience, analysts believe Bionano Genomics is more attractive than Harvard Bioscience.

    Company Buy Ratings Hold Ratings Sell Ratings
    HBIO
    Harvard Bioscience
    2 0 0
    BNGO
    Bionano Genomics
    0 2 0
  • Is HBIO or BNGO More Risky?

    Harvard Bioscience has a beta of 1.464, which suggesting that the stock is 46.371% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.247, suggesting its more volatile than the S&P 500 by 124.652%.

  • Which is a Better Dividend Stock HBIO or BNGO?

    Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HBIO or BNGO?

    Harvard Bioscience quarterly revenues are $24.6M, which are larger than Bionano Genomics quarterly revenues of $6.1M. Harvard Bioscience's net income of $18K is higher than Bionano Genomics's net income of -$44.2M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.30x versus 0.08x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HBIO
    Harvard Bioscience
    0.30x -- $24.6M $18K
    BNGO
    Bionano Genomics
    0.08x -- $6.1M -$44.2M
  • Which has Higher Returns HBIO or BRKR?

    Bruker has a net margin of 0.07% compared to Harvard Bioscience's net margin of 1.4%. Harvard Bioscience's return on equity of -18.36% beat Bruker's return on equity of 6.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    HBIO
    Harvard Bioscience
    57.06% -- $100.3M
    BRKR
    Bruker
    50.36% $0.09 $3.9B
  • What do Analysts Say About HBIO or BRKR?

    Harvard Bioscience has a consensus price target of $4.25, signalling upside risk potential of 555.97%. On the other hand Bruker has an analysts' consensus of $68.42 which suggests that it could grow by 48.86%. Given that Harvard Bioscience has higher upside potential than Bruker, analysts believe Harvard Bioscience is more attractive than Bruker.

    Company Buy Ratings Hold Ratings Sell Ratings
    HBIO
    Harvard Bioscience
    2 0 0
    BRKR
    Bruker
    7 5 0
  • Is HBIO or BRKR More Risky?

    Harvard Bioscience has a beta of 1.464, which suggesting that the stock is 46.371% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.406%.

  • Which is a Better Dividend Stock HBIO or BRKR?

    Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.44% to investors and pays a quarterly dividend of $0.05 per share. Harvard Bioscience pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HBIO or BRKR?

    Harvard Bioscience quarterly revenues are $24.6M, which are smaller than Bruker quarterly revenues of $979.6M. Harvard Bioscience's net income of $18K is lower than Bruker's net income of $13.7M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Bruker's PE ratio is 60.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.30x versus 2.04x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HBIO
    Harvard Bioscience
    0.30x -- $24.6M $18K
    BRKR
    Bruker
    2.04x 60.47x $979.6M $13.7M
  • Which has Higher Returns HBIO or KMTS?

    Kestra Medical Technologies has a net margin of 0.07% compared to Harvard Bioscience's net margin of --. Harvard Bioscience's return on equity of -18.36% beat Kestra Medical Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HBIO
    Harvard Bioscience
    57.06% -- $100.3M
    KMTS
    Kestra Medical Technologies
    -- -- --
  • What do Analysts Say About HBIO or KMTS?

    Harvard Bioscience has a consensus price target of $4.25, signalling upside risk potential of 555.97%. On the other hand Kestra Medical Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Harvard Bioscience has higher upside potential than Kestra Medical Technologies, analysts believe Harvard Bioscience is more attractive than Kestra Medical Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    HBIO
    Harvard Bioscience
    2 0 0
    KMTS
    Kestra Medical Technologies
    0 0 0
  • Is HBIO or KMTS More Risky?

    Harvard Bioscience has a beta of 1.464, which suggesting that the stock is 46.371% more volatile than S&P 500. In comparison Kestra Medical Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HBIO or KMTS?

    Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Kestra Medical Technologies pays out -1.99% of its earnings as a dividend.

  • Which has Better Financial Ratios HBIO or KMTS?

    Harvard Bioscience quarterly revenues are $24.6M, which are larger than Kestra Medical Technologies quarterly revenues of --. Harvard Bioscience's net income of $18K is higher than Kestra Medical Technologies's net income of --. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Kestra Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.30x versus 21.49x for Kestra Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HBIO
    Harvard Bioscience
    0.30x -- $24.6M $18K
    KMTS
    Kestra Medical Technologies
    21.49x -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock